| Name | Title | Contact Details |
|---|---|---|
Taylor Cucchiara |
Associate Director, Cybersecurity | Profile |
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.
Anika is a biomedical joint preservation company that leverages proprietary regenerative and restoration therapies to help people feel better faster and remain active. For nearly 30 years and 35 million procedures worldwide, Anika has been passionately advancing quality patient care by enabling people to continue doing what they love. Anika. Your life. In Motion.